Loqtorzi
Loqtorzi ingredients
| Active ingredient | Strength |
|---|---|
| Toripalimab | 240 mg/6mL |
What Loqtorzi is used for
The FDA lists the approved uses on the official label (below). In the EU, toripalimab is approved as Loqtorzi for:
Loqtorzi, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma. Loqtorzi, in combination with cisplatin and paclitaxel, is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Loqtorzi
- Generic name
- Toripalimab-tpzi
- Made by
- Coherus Oncology, Inc.
- Forms
- Injection
- Given
- Intravenous
- Drug class
- Programmed Death Receptor-1 Blocking Antibody
- FDA approval
- Biologic licence (BLA) BLA761240
- On the US market since
- 2023
Official information
- Loqtorzi prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Toripalimab-tpzi)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Loqtorzi?
Loqtorzi (Toripalimab-tpzi) is a cancer medicine made by Coherus Oncology, Inc., approved by the US FDA.
What are the ingredients of Loqtorzi?
Loqtorzi contains Toripalimab (240 mg/6mL).
Is Loqtorzi approved in Europe?
The same active substance is approved in the EU as Loqtorzi.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA